Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.07, Briefing.com reports. The company had revenue of $1.00 million for the quarter. During the same period in the previous year, the company earned ($0.63) EPS. Xenon Pharmaceuticals's revenue for the quarter was up .0% compared to the same quarter last year.
Xenon Pharmaceuticals Stock Down 4.6 %
NASDAQ:XENE traded down $1.95 during mid-day trading on Friday, hitting $40.54. 527,882 shares of the stock traded hands, compared to its average volume of 390,433. Xenon Pharmaceuticals has a 52 week low of $27.99 and a 52 week high of $50.99. The firm's 50 day moving average is $42.75 and its two-hundred day moving average is $41.57. The stock has a market capitalization of $3.06 billion, a price-to-earnings ratio of -14.90 and a beta of 1.19.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the stock. Royal Bank of Canada cut their target price on shares of Xenon Pharmaceuticals from $56.00 to $55.00 and set an "outperform" rating on the stock in a research note on Friday, March 1st. Citigroup lowered their price objective on Xenon Pharmaceuticals from $62.00 to $60.00 and set a "buy" rating on the stock in a research report on Friday. Needham & Company LLC restated a "buy" rating and set a $62.00 target price on shares of Xenon Pharmaceuticals in a research note on Friday. Wedbush reduced their price target on shares of Xenon Pharmaceuticals from $51.00 to $50.00 and set an "outperform" rating for the company in a research note on Friday. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday, April 10th. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $59.11.
Read Our Latest Research Report on Xenon Pharmaceuticals
Insider Transactions at Xenon Pharmaceuticals
In related news, EVP Sherrington Robin sold 7,137 shares of the business's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total value of $330,300.36. Following the completion of the sale, the executive vice president now owns 8,398 shares in the company, valued at $388,659.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Steven Gannon sold 13,000 shares of the firm's stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $601,640.00. Following the sale, the director now directly owns 2,000 shares in the company, valued at approximately $92,560. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sherrington Robin sold 7,137 shares of the business's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $330,300.36. Following the transaction, the executive vice president now owns 8,398 shares of the company's stock, valued at approximately $388,659.44. The disclosure for this sale can be found here. Company insiders own 5.43% of the company's stock.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
See Also
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
